Natixis Investment Managers International Vertex Pharmaceuticals Inc Transaction History

Natixis Investment Managers International

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 11, 2023	SELL	$314.42 - $351.91 $1.96 Million - $2.19 Million	-6,225 Reduced 6.59%	88,235 $31.1 Million
Q1 2023 May 12, 2023	SELL	$283.23 - $323.1 $4.77 Million - $5.44 Million	-16,840 Reduced 15.13%	94,460 $29.8 Million
Q4 2022 Feb 13, 2023	SELL	$285.76 - $321.48 $4.24 Million - $4.77 Million	-14,825 Reduced 11.75%	111,300 $32.1 Million
Q3 2022 Nov 14, 2022	SELL	$273.83 - $305.53 $26.7 Million - $29.8 Million	-97,650 Reduced 43.64%	126,125 $36.5 Million
Q2 2022 Aug 12, 2022	SELL	$234.96 - $292.55 $1.13 Million - $1.41 Million	-4,830 Reduced 2.11%	223,775 $63.1 Million
Q1 2022 May 13, 2022	SELL	$221.42 - $260.97 $5.78 Million - $6.82 Million	-26,125 Reduced 10.26%	228,605 $59.7 Million
Q4 2021 Feb 14, 2022	BUY	$177.01 - $223.45 $45.1 Million - $56.9 Million	254,730 New	254,730 $55.9 Million
Q4 2018 Feb 14, 2019	SELL	$151.91 - $192.21 $1.13 Million - $1.42 Million	-7,409 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$167.73 - $192.74 $361,122 - $414,969	2,153 Added 40.96%	7,409 $1.43 Million
Q2 2018 Aug 14, 2018	SELL	$145.72 - $169.96 $602,260 - $702,444	-4,133 Reduced 44.02%	5,256 $894,000
Q1 2018 May 15, 2018	BUY	$151.6 - $177.13 $1.42 Million - $1.66 Million	9,389 New	9,389 $1.53 Million
Q4 2017 Feb 14, 2018	SELL	$137.28 - $155.55 $705,893 - $799,838	-5,142 Closed	0 $0
Q3 2017 Nov 14, 2017	BUY	$148.13 - $162.24 $761,684 - $834,238	5,142	5,142 $782,000

1,705

221M

1.58M

1.36M

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $119B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

Get notified when there are updates to the investment portfolio of Natixis Investment Managers International, based on Form 13F filings with the SEC.

Stay updated on Natixis Investment Managers International with notifications on news.